|
多形性胶质母细胞瘤患者放疗和替莫唑胺治疗后对福莫司汀和贝伐单抗的反应 摘要：多形性胶质母细胞瘤是原发性中枢神经系统肿瘤中最常见的类型，显著特征为生存期短、对化疗药物反应不明显，且复发率较高，无有效的二线治疗药物。在这项研究中，病人接受了soffietti治疗方案：诱导期第1天及第8天服用福莫司汀75 mg/m2，第1天和第15天接贝伐单抗10 mg/kg；维持期内，每三周为一周期服用福莫司汀75 mg/m2及贝伐单抗10 mg/kg，共计两个周期。随后的磁共振成像显示手术后变化为：左枕水平位置无增强，毒性左脑白质病无质量效应及肿瘤细胞残留。随后病人在肺血栓栓塞症发生前，一直接受贝伐单抗单药维持治疗。肿瘤复发后，继续使用福莫司汀维持治疗。该患者病情一直较为稳定，直到他因肺血栓栓塞和感染并发症去世。 关键词：贝伐单抗，脑肿瘤，福莫司汀 Complete response with fotemustine and bevacizumab after early progression following radiotherapy and temozolomide treatment in patient with glioblastoma multiforme Ovidio Fernández Calvo, María Eva Pérez López, Jesús García Gómez
Glioblastoma multiforme is the most common type of primary central nervous system tumor and is noted for its short survival and poor response to chemotherapeutic agents. Unfortunately, the relapse rate is very high, and there is no reference drug for second-line treatment. In this study, a patient was treated with the Soffietti regimen. The induction phase was fotemustine 75 mg/m 2 at day 1 and day 8 and bevacizumab 10 mg/kg at day 1 and day 15. The maintenance phase was fotemustine 75 mg/m 2 and bevacizumab 10 mg/kg every 3 weeks for two cycles. Follow-up magnetic resonance imaging showed post-surgical changes at the left occipital level, without contrast enhancement, and toxic left leuko-encephalopathy post-treatment without mass effect and with no evidence of tumor residue. The patient then was maintained with bevacizumab monotherapy until it was withdrawn when pulmonary thromboembolism occurred. Following tumor regrowth, fotemustine was started again as maintenance therapy. The patient achieved stabilization of his disease until his death due to thromboembolic and infectious complications. Key words: Bevacizumab, brain tumor, fotemustine （How to cite this article: Calvo OF, Pérez López ME, Gómez JG. Complete response with fotemustine and bevacizumab after early progression following radiotherapy and temozolomide treatment in patient with glioblastoma multiforme. J Cancer Metastasis Treat 2015;1:36-8） |
|
|
